Is Insulin Introduction Disadvantageous Compared to Delaying or Avoiding Insulin in Type 2 Diabetes?
Insulin introduction is not inherently disadvantageous when used appropriately, but delaying insulin initiation with GLP-1 receptor agonists and SGLT2 inhibitors is now preferred in most patients with type 2 diabetes to minimize risks of hypoglycemia, weight gain, and potentially adverse cardiovascular outcomes.
Current Evidence-Based Approach to Insulin Timing
The most recent ADA/EASD consensus guidelines (2022) fundamentally shifted the paradigm around insulin use in type 2 diabetes 1. With the availability of multiple glucose-lowering agents that provide cardiorenal protection beyond glycemic control, insulin initiation can be postponed to later stages of disease in many patients. GLP-1 receptor agonists should be considered in all patients without contraindications before initiating insulin therapy, as they achieve lower glycemic targets with lower injection burden and reduced risks of hypoglycemia and weight gain compared to insulin alone 1.
When Insulin Should NOT Be Delayed
However, insulin remains the preferred first-line agent in specific circumstances 1:
- Severe hyperglycemia (HbA1c >10% or >86 mmol/mol), particularly with:
- Weight loss
- Ketonuria/ketosis
- Catabolic features
- Acute glycemic dysregulation (hospitalization, surgery, acute illness)
- Underweight patients
- Suspected type 1 diabetes
In these situations, insulin introduction should not be delayed 1, 2.
Evidence of Disadvantages with Insulin Use
Cardiovascular and Mortality Risks
Recent observational research raises concerning signals about insulin therapy. A 2025 retrospective cohort study found that compared to non-insulin treatment intensification, insulin therapy was associated with significantly higher risks 3:
- MACE (major adverse cardiovascular events): adjusted HR 2.78 (95% CI 2.64-2.92)
- All-cause mortality: adjusted HR 4.74 (95% CI 4.63-4.85)
Importantly, the smallest risk increases occurred in patients who had previously used three non-insulin drugs before initiating insulin (MACE HR: 2.62; mortality HR: 3.05), and among insulin types, long-acting insulin showed the lowest risk increases (MACE HR: 1.34; mortality HR: 1.90) 3.
A 2020 study in Medicaid enrollees found that regardless of timing, insulin users had approximately 2-fold higher CVD risk compared to non-insulin users, with only borderline increases in CVD risk after insulin initiation itself 4. This suggests the elevated risk may reflect disease severity rather than insulin per se, though the distinction matters less for clinical decision-making.
Metabolic and Safety Concerns
Beyond cardiovascular outcomes, insulin therapy carries well-established disadvantages 1, 5:
- Hypoglycemia risk: Particularly problematic in older adults where it can cause devastating outcomes including falls, cognitive impairment, and cardiovascular events
- Weight gain: Counterproductive in the majority of type 2 diabetes patients who have obesity
- Increased treatment complexity: Multiple daily injections, frequent glucose monitoring, dose titration requirements
- Reduced adherence: Fear of hypoglycemia and needle phobia lead to delays in initiation and poor persistence
The 2019 Endocrine Society guidelines for older adults specifically note that insulin-related hypoglycemia is associated with poorer medication adherence and increased work absences 5.
Consequences of Delayed Insulin Initiation
While avoiding premature insulin has advantages, excessive delay when insulin is truly needed also carries risks. A 2026 Thai study found that delayed insulin initiation (≥6 months after documented treatment failure) occurred in 35% of patients and was associated with 6:
- Increased amputation risk: HR 2.33 (95% CI 1.07-5.07)
- Earlier onset of microvascular complications within 10-15 years
This highlights the critical distinction between appropriate delay (using superior alternatives like GLP-1 RAs and SGLT2 inhibitors) versus therapeutic inertia (failing to intensify therapy when needed).
Practical Algorithm for Insulin Decision-Making
Step 1: Assess for Immediate Insulin Need
- HbA1c >10% with symptoms/catabolism → Start insulin immediately 1, 2, 7
- Acute illness, surgery, hospitalization → Start insulin temporarily 1, 7
- Suspected type 1 diabetes → Start insulin immediately 1
Step 2: For Non-Urgent Situations (HbA1c 7-10%)
Prioritize non-insulin agents first 1, 8, 9:
- Ensure metformin is on board (unless contraindicated by eGFR <30)
- Add GLP-1 receptor agonist (especially semaglutide or tirzepatide for maximal efficacy)
- Add SGLT2 inhibitor (particularly if CVD, CKD, or heart failure present)
- Consider combination of GLP-1 RA + SGLT2 inhibitor before insulin 8, 9
Step 3: When to Finally Initiate Insulin
Only after maximizing non-insulin therapies and still not achieving glycemic targets 1:
- Start with basal insulin (glargine U300 or degludec preferred over NPH for lower hypoglycemia risk) 1, 5
- Discontinue sulfonylureas when starting insulin to reduce hypoglycemia 1
- Continue metformin, GLP-1 RA, and SGLT2 inhibitor with insulin 2
- Use long-acting insulin analogs rather than intermediate-acting to minimize hypoglycemia and mortality risk 3
Step 4: Intensification if Needed
- Add prandial insulin before largest meal first (basal-plus) 10
- Progress to basal-bolus if needed 1
- Consider adding GLP-1 RA to basal insulin before adding prandial insulin 5
Critical Pitfalls to Avoid
Starting insulin prematurely when GLP-1 RAs or SGLT2 inhibitors haven't been tried—these offer superior cardiorenal protection without insulin's risks 1, 8, 9
Therapeutic inertia when insulin is truly needed—don't delay beyond 6 months after documented treatment failure on maximal non-insulin therapy 6
Using intermediate-acting insulin (NPH) when long-acting analogs are available—they have lower hypoglycemia and potentially lower mortality risk 1, 3
Continuing sulfonylureas after starting insulin—this compounds hypoglycemia risk unnecessarily 1
Inadequate patient education about hypoglycemia recognition, glucose monitoring, and injection technique before insulin initiation 7
Ignoring weight management—insulin causes weight gain, so concurrent use of weight-neutral or weight-reducing agents (GLP-1 RAs, SGLT2 inhibitors) is essential 11
Special Populations
Older adults (≥65 years): Exercise particular caution with insulin due to elevated hypoglycemia risk and its devastating consequences (falls, cognitive impairment). Consider higher glycemic targets (HbA1c 7.5-8%) and prioritize hypoglycemia avoidance over tight control 5.
Patients with established CVD/CKD: Prioritize GLP-1 RAs and SGLT2 inhibitors over insulin for their proven cardiovascular and renal benefits. If insulin is needed, use it in combination with these agents rather than as monotherapy 2, 11, 8, 9.
Patients with obesity: GLP-1 RAs (especially tirzepatide, semaglutide) should be strongly preferred over insulin given their weight loss effects versus insulin's weight gain 11, 8.